KPW
BCLI

Kore Private Wealth’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Kore Private Wealth’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-267
Closed -$44K – 351
2020
Q2 		$44K Hold
267
– – 0.01% 481
2020
Q1 		$19K Hold
267
– – ﹤0.01% 596
2019
Q4 		$17K Buy
+267
New +$15.5K ﹤0.01% 652
2019
Q2 		– Sell
-267
Closed -$17K – 283
2019
Q1 		$17K Hold
267
– – ﹤0.01% 525
2018
Q4 		$14K Buy
+267
New +$13.2K ﹤0.01% 533

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Kore Private Wealth's BCLI Position: Q3 2020 in Review

Kore Private Wealth sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2020, closing a stake of 267 shares — an estimated $44K sold.

Kore Private Wealth first reported a position in BCLI in Q4 2018 and held it in 5 quarters. The position peaked at $44K in Q2 2020. 80 funds tracked by Wall St. Rank hold BCLI as of Q3 2020.

  • Kore Private Wealth reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 267 BRAINSTORM CELL THERAPUTC shares in Q3 2020, an estimated $44K.
  • Kore Private Wealth first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2018 and held it in 5 quarters.
  • Kore Private Wealth's BRAINSTORM CELL THERAPUTC position peaked at $44K in Q2 2020.
  • 80 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.